iShares Biotechnology ETF
IBB - US stocks
IBB seeks to track the performance of the ICE Biotechnology Index, which contains the stocks of US-listed companies in the biotechnology area, including research, development, and production of pharmaceuticals and production of tools or systems used in biotechnology processes. The fund is appropriate for those seeking long-term growth. The fund is subject to equity market risk and concentration risk, as the basket of securities held by the fund is smaller and less diversified than a broad index fund.
When IBB declines in value, we’ll automatically sell it and buy the alternate as part of our tax-loss harvesting strategy.
Alternate
BBH
VanEck Biotech ETF
US stocks
- Price$140.22as of 01:45 PM EST, 12/11/2024
- Risk ratingVery highWe base risk ratings on the volatility, or the size and frequency of price fluctuations, of the investment. Typically, a more volatile investment has a higher risk rating.
- Expense ratio0.45%The percentage of fund assets used to cover operating expenses and management fees.
- 52-week high$150.56The highest share price in the past year.
- 52-week low$123.56The lowest share price in the past year.
- Dividend yield0.32%The average percentage of dividends paid relative to the share price over the past year.
- Net assets$6.87BThe total value of all assets held by the fund.
- Volume1,310,995The average trading volume over the past 90 days.
Investing is easy
when it’s automated
Start with one of Wealthfront’s expert-built portfolios and then customize your portfolio with hundreds of investment possibilities.